Reported Earnings • Apr 25
Full year 2025 earnings released: EPS: CN¥0.28 (vs CN¥0.25 in FY 2024) Full year 2025 results: EPS: CN¥0.28 (up from CN¥0.25 in FY 2024). Revenue: CN¥1.37b (up 3.4% from FY 2024). Net income: CN¥69.8m (up 12% from FY 2024). Profit margin: 5.1% (up from 4.7% in FY 2024). Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has increased by 4% per year. Announcement • Apr 25
Qingdao Vland Biotech INC., Annual General Meeting, May 15, 2026 Qingdao Vland Biotech INC., Annual General Meeting, May 15, 2026, at 14:30 China Standard Time. Location: Block B, No. 596-1, Jiushui East Road, Laoshan District, Qingdao, Shandong China Announcement • Mar 30
Qingdao Vland Biotech INC. to Report Q1, 2026 Results on Apr 25, 2026 Qingdao Vland Biotech INC. announced that they will report Q1, 2026 results on Apr 25, 2026 Valuation Update With 7 Day Price Move • Mar 23
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to CN¥13.30, the stock trades at a trailing P/E ratio of 40.3x. Average trailing P/E is 42x in the Biotechs industry in China. Total loss to shareholders of 5.5% over the past three years. New Risk • Jan 29
New major risk - Revenue and earnings growth Earnings have declined by 14% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 14% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Valuation Update With 7 Day Price Move • Jan 14
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥16.71, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 26x in the Biotechs industry in China. Total returns to shareholders of 24% over the past three years. Announcement • Dec 26
Qingdao Vland Biotech INC. to Report Fiscal Year 2025 Results on Apr 25, 2026 Qingdao Vland Biotech INC. announced that they will report fiscal year 2025 results on Apr 25, 2026 Reported Earnings • Oct 30
Third quarter 2025 earnings released: EPS: CN¥0.12 (vs CN¥0.042 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.12 (up from CN¥0.042 in 3Q 2024). Revenue: CN¥363.6m (up 8.1% from 3Q 2024). Net income: CN¥35.1m (up 205% from 3Q 2024). Profit margin: 9.6% (up from 3.4% in 3Q 2024). Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Announcement • Sep 30
Qingdao Vland Biotech INC. to Report Q3, 2025 Results on Oct 29, 2025 Qingdao Vland Biotech INC. announced that they will report Q3, 2025 results on Oct 29, 2025 Announcement • Jun 30
Qingdao Vland Biotech INC. to Report First Half, 2025 Results on Aug 28, 2025 Qingdao Vland Biotech INC. announced that they will report first half, 2025 results on Aug 28, 2025 Buy Or Sell Opportunity • Jun 19
Now 20% undervalued The stock has been flat over the last 90 days, currently trading at CN¥12.86. The fair value is estimated to be CN¥16.09, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.8% over the last 3 years. Earnings per share has declined by 17%. Revenue is forecast to grow by 19% in 2 years. Earnings are forecast to grow by 77% in the next 2 years. Declared Dividend • May 28
Dividend of CN¥0.10 announced Dividend of CN¥0.10 is the same as last year. Ex-date: 30th May 2025 Payment date: 30th May 2025 Dividend yield will be 0.7%, which is lower than the industry average of 1.6%. Sustainability & Growth Dividend is well covered by both earnings (41% earnings payout ratio) and cash flows (29% cash payout ratio). The dividend has decreased over the past 66 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 86% over the next 3 years, which should provide support to the dividend and adequate earnings cover. New Risk • May 17
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 40% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (4.4% net profit margin). Reported Earnings • Apr 27
First quarter 2025 earnings released: EPS: CN¥0.04 (vs CN¥0.05 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.04 (down from CN¥0.05 in 1Q 2024). Revenue: CN¥310.2m (up 8.2% from 1Q 2024). Net income: CN¥9.58m (down 25% from 1Q 2024). Profit margin: 3.1% (down from 4.4% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.7% p.a. on average during the next 2 years, compared to a 28% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. Announcement • Apr 26
Qingdao Vland Biotech INC., Annual General Meeting, May 16, 2025 Qingdao Vland Biotech INC., Annual General Meeting, May 16, 2025, at 14:30 China Standard Time. Location: Block B, No. 596-1, Jiushui East Road, Laoshan District, Qingdao, Shandong China Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to CN¥16.21, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 24x in the Biotechs industry in China. Total loss to shareholders of 2.1% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥20.66 per share. Announcement • Mar 28
Qingdao Vland Biotech INC. to Report Q1, 2025 Results on Apr 26, 2025 Qingdao Vland Biotech INC. announced that they will report Q1, 2025 results on Apr 26, 2025 Announcement • Dec 27
Qingdao Vland Biotech INC. to Report Fiscal Year 2024 Results on Apr 26, 2025 Qingdao Vland Biotech INC. announced that they will report fiscal year 2024 results on Apr 26, 2025 Valuation Update With 7 Day Price Move • Nov 18
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥13.25, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 26x in the Biotechs industry in China. Total loss to shareholders of 25% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥7.66 per share. Reported Earnings • Oct 30
Third quarter 2024 earnings released: EPS: CN¥0.042 (vs CN¥0.10 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.042 (down from CN¥0.10 in 3Q 2023). Revenue: CN¥336.4m (flat on 3Q 2023). Net income: CN¥11.5m (down 52% from 3Q 2023). Profit margin: 3.4% (down from 7.1% in 3Q 2023). Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Oct 24
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥13.49, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 26x in the Biotechs industry in China. Total loss to shareholders of 18% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥7.06 per share. Announcement • Sep 30
Qingdao Vland Biotech INC. to Report Q3, 2024 Results on Oct 29, 2024 Qingdao Vland Biotech INC. announced that they will report Q3, 2024 results on Oct 29, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to CN¥12.76, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 22x in the Biotechs industry in China. Total loss to shareholders of 31% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥6.98 per share. Announcement • Jun 28
Qingdao Vland Biotech INC. to Report First Half, 2024 Results on Aug 28, 2024 Qingdao Vland Biotech INC. announced that they will report first half, 2024 results on Aug 28, 2024 Valuation Update With 7 Day Price Move • May 27
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥15.52, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 23x in the Biotechs industry in China. Total loss to shareholders of 9.1% over the past three years. New Risk • May 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 9.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Large one-off items impacting financial results. New Risk • May 06
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 28% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Valuation Update With 7 Day Price Move • May 02
Investor sentiment improves as stock rises 33% After last week's 33% share price gain to CN¥13.87, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 25x in the Biotechs industry in China. Total loss to shareholders of 16% over the past three years. Announcement • Apr 27
Qingdao Vland Biotech INC., Annual General Meeting, May 16, 2024 Qingdao Vland Biotech INC., Annual General Meeting, May 16, 2024, at 14:30 China Standard Time. Location: Block B, No. 596-1, Jiushui East Road, Laoshan District, Qingdao, Shandong China Reported Earnings • Apr 26
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥0.32 (up from CN¥0.28 in FY 2022). Revenue: CN¥1.20b (up 3.1% from FY 2022). Net income: CN¥80.7m (up 16% from FY 2022). Profit margin: 6.7% (up from 6.0% in FY 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 6.4%. Earnings per share (EPS) also missed analyst estimates by 30%. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to CN¥9.05, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 22x in the Biotechs industry in China. Total loss to shareholders of 50% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥4.66 per share. Announcement • Mar 29
Qingdao Vland Biotech INC. to Report Q1, 2024 Results on Apr 26, 2024 Qingdao Vland Biotech INC. announced that they will report Q1, 2024 results on Apr 26, 2024 New Risk • Feb 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.6% average weekly change). Large one-off items impacting financial results. Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥10.13, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 23x in the Biotechs industry in China. Total loss to shareholders of 34% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥7.41 per share. Announcement • Dec 29
Qingdao Vland Biotech INC. to Report Fiscal Year 2023 Results on Apr 26, 2024 Qingdao Vland Biotech INC. announced that they will report fiscal year 2023 results on Apr 26, 2024 Valuation Update With 7 Day Price Move • Dec 26
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥16.60, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 29x in the Biotechs industry in China. Total returns to shareholders of 4.7% over the past three years. Reported Earnings • Oct 31
Third quarter 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.07 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.10 (up from CN¥0.07 in 3Q 2022). Revenue: CN¥335.7m (up 13% from 3Q 2022). Net income: CN¥23.9m (up 42% from 3Q 2022). Profit margin: 7.1% (up from 5.7% in 3Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 28
Second quarter 2023 earnings released: EPS: CN¥0.08 (vs CN¥0.08 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.08 (in line with 2Q 2022). Revenue: CN¥311.4m (up 13% from 2Q 2022). Net income: CN¥20.9m (up 8.2% from 2Q 2022). Profit margin: 6.7% (down from 7.0% in 2Q 2022). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. Announcement • Aug 18
Qingdao Vland Biotech INC. (SHSE:603739) completed the acquisition of 51% stake in Qingdao RBT Biotechnology Co., Ltd. from Qingdao Jurun Management Consulting Partnership (Limited Partnership), Qingdao Gerunpu Management Consulting Partnership (Limited Partnership) and other individual shareholders. Qingdao Vland Biotech INC. (SHSE:603739) signed a share transfer agreement to acquire a 51% stake in Qingdao RBT Biotechnology Co., Ltd. from Qingdao Jurun Management Consulting Partnership (Limited Partnership), Qingdao Gerunpu Management Consulting Partnership (Limited Partnership) and other individual shareholders for CNY 91.8 million on July 20, 2023. Under the terms, Qingdao Vland Biotech will pay 60% consideration within 3 working days from the date of completing the industrial and commercial change and the remaining 40% equity transfer payment subject to performance commitment in 2023, 2024, and 2025, to be paid every next year. As part of the transaction, Qin Wei will sell 22% stake, 6.25% by Qin Qilong, 4.25% by Zhang Xiaodong, 2% by Chen Qiang, 9% by Qingdao Jurun Management Consulting Partnership and 7.5% by Qingdao Gerunpu Management Consulting. As of March 31, 2023, Qingdao RBT Biotechnology reported total assets of CNY 83.2244 million and net assets of CNY 56.4629 million. The transaction is approved by the board of Qingdao Vland Biotech and does not need to be submitted to the general meeting of shareholders for consideration.
Qingdao Vland Biotech INC. (SHSE:603739) completed the acquisition of 51% stake in Qingdao RBT Biotechnology Co., Ltd. from Qingdao Jurun Management Consulting Partnership (Limited Partnership), Qingdao Gerunpu Management Consulting Partnership (Limited Partnership) and other individual shareholders on August 16, 2023. Reported Earnings • Apr 28
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: CN¥0.28 (down from CN¥0.54 in FY 2021). Revenue: CN¥1.16b (up 1.1% from FY 2021). Net income: CN¥69.8m (down 47% from FY 2021). Profit margin: 6.0% (down from 12% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 4.9%. Earnings per share (EPS) also missed analyst estimates by 33%. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 6% per year. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Supervisor Jing Shao was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 29
Third quarter 2022 earnings released: EPS: CN¥0.07 (vs CN¥0.13 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.07 (down from CN¥0.13 in 3Q 2021). Revenue: CN¥296.8m (up 4.7% from 3Q 2021). Net income: CN¥16.8m (down 49% from 3Q 2021). Profit margin: 5.7% (down from 12% in 3Q 2021). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 24
Second quarter 2022 earnings released: EPS: CN¥0.08 (vs CN¥0.13 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.08 (down from CN¥0.13 in 2Q 2021). Revenue: CN¥276.6m (down 2.2% from 2Q 2021). Net income: CN¥19.3m (down 40% from 2Q 2021). Profit margin: 7.0% (down from 11% in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Apr 21
First quarter 2022 earnings released: EPS: CN¥0.07 (vs CN¥0.14 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.07 (down from CN¥0.14 in 1Q 2021). Revenue: CN¥256.0m (down 3.8% from 1Q 2021). Net income: CN¥18.1m (down 38% from 1Q 2021). Profit margin: 7.1% (down from 11% in 1Q 2021). Over the next year, revenue is forecast to grow 28%, compared to a 48% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Reported Earnings • Oct 31
Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.14 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: CN¥283.5m (up 8.5% from 3Q 2020). Net income: CN¥33.2m (up 14% from 3Q 2020). Profit margin: 12% (in line with 3Q 2020). Reported Earnings • Aug 18
Second quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.10 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥283.0m (up 20% from 2Q 2020). Net income: CN¥32.3m (up 46% from 2Q 2020). Profit margin: 11% (up from 9.4% in 2Q 2020). The increase in margin was driven by higher revenue. Reported Earnings • Apr 25
First quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.14 in 1Q 2020) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2021 results: Revenue: CN¥266.2m (up 36% from 1Q 2020). Net income: CN¥29.0m (up 33% from 1Q 2020). Profit margin: 11% (in line with 1Q 2020). Announcement • Apr 09
Qingdao Vland Biotech INC. announced that it has received CNY 499.999984 million in funding from Tibet Shancheng Investment Consulting Co., Ltd., Tibet Sizhuang Investment Consulting Co., Ltd. On April 8, 2021, Qingdao Vland Biotech INC. (SHSE:603739) closed the transaction. The company paid issuance cost of CNY 4,045,283.04 and received net proceeds of CNY 495,954,700.96 in the transaction. Is New 90 Day High Low • Dec 28
New 90-day low: CN¥20.71 The company is down 14% from its price of CN¥24.00 on 29 September 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. Is New 90 Day High Low • Dec 08
New 90-day low: CN¥23.67 The company is down 4.0% from its price of CN¥24.75 on 09 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 6.0% over the same period. Reported Earnings • Oct 29
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥103.0m, up 31% from the prior year. Total revenue was CN¥922.5m over the last 12 months, up 9.8% from the prior year. Announcement • Oct 18
Qingdao Vland Biotech INC. announced that it expects to receive CNY 499.999984 million in funding from Tibet Shancheng Investment Consulting Co., Ltd., Tibet Sizhuang Investment Consulting Co., Ltd. Qingdao Vland Biotech Inc. (SHSE:603739) announced private placement of 25,393,600 shares at a price of CNY 19.69 per share for gross proceeds of CNY 499,999,984 on October 16, 2020. The transaction includes participation from Tibet Shancheng Investment Consulting Co., Ltd. and Tibet Sizhuang Investment Consulting Co., Ltd. for 12,696,800 shares each. The shares subscribed shall not be transferred within 18 months from the end of the issuance. The transaction is approved at the 4th meeting of the 4th board of directors of the company. The transaction is subject to approval of company’s shareholders and the China Securities Regulatory Commission before closing. The shareholder's approval is valid for 12 months. Announcement • Jul 10
Qingdao Vland Biotech INC. to Report First Half, 2020 Results on Aug 27, 2020 Qingdao Vland Biotech INC. announced that they will report first half, 2020 results on Aug 27, 2020 
